9-(4-butylphenyl)-10-fluoro-6,11-dihydro-5H-benzo[a]carbazole-3-carboxylic acid | 920302-12-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 9-(4-butylphenyl)-10-fluoro-6,11-dihydro-5H-benzo[a]carbazole-3-carboxylic acid
• CAS: 920302-12-1
• 化学式: C₂₇H₂₄FNO₂
• 分子量: 413.491
• InChiKey: INVHKKQZPYHSEW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  7.1
• 重原子数：
  31
• 可旋转键数：
  5
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  53.1
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  4-[(4-甲基苯基)磺酰基]哌啶盐酸盐 、 (4'-Butyl-2-fluoro-biphenyl-3-yl)-hydrazine hydrochloride 在 溶剂黄146 、 zinc(II) chloride 作用下， 生成 9-(4-butylphenyl)-10-fluoro-6,11-dihydro-5H-benzo[a]carbazole-3-carboxylic acid
  参考文献：
  名称：

  Discovery and biological evaluation of benzo[a]carbazole-based small molecule agonists of the thrombopoietin (Tpo) receptor

  摘要：

  A novel series of benzo[a] carbazole-based small molecule agonists of the thrombopoietin (Tpo) receptor is reported. Starting from a 3.4 mu M high throughput screen hit, members of this series have been identified which are full agonists with functional potency < 50 nM and oral bioavailability in mice. (C) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2008.08.068

文献信息

• HETEROTETRACYCLIC COMPOUNDS AS TPO MIMETICS
  申请人：Alper Phillip B.

  公开号：US20090075996A1

  公开（公告）日：2009-03-19

  The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated TPO activity, particularly diseases or disorders that involve thrombocytopenia.

  该发明提供了一类新颖的化合物，包括含有这些化合物的药物组合物，以及使用这些化合物来治疗或预防与TPO活性异常或失调相关的疾病或障碍的方法，尤其是涉及血小板减少症的疾病或障碍。
• HETEROTETRACYCLIC COMPOUNDS AS TPO MIMETICS
  申请人：IRM, LLC

  公开号：EP1910338B1

  公开（公告）日：2010-08-25
• US8153671B2
  申请人：——

  公开号：US8153671B2

  公开（公告）日：2012-04-10
• [EN] COMPOUNDS AND COMPOSITIONS AS TPO MIMETICS<br/>[FR] COMPOSES ET COMPOSITIONS UTILISES COMME MIMETIQUES DE LA TPO
  申请人：IRM LLC

  公开号：WO2007009120A2

  公开（公告）日：2007-01-18

  [EN] The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated TPO activity, particularly diseases or disorders that involve thrombocytopenia.
  [FR] La présente invention concerne une nouvelle classe de composés, des compositions pharmaceutiques comprenant ces composés et des procédés d'utilisation de tels composés pour traiter ou prévenir des maladies ou des troubles associés à une activité anormale ou déréglée de la thrombopoïétine (TPO), en particulier des maladies ou des troubles impliquant la thrombocytopénie.
• Discovery and biological evaluation of benzo[a]carbazole-based small molecule agonists of the thrombopoietin (Tpo) receptor
  作者：Phil B. Alper、Thomas H. Marsilje、Daniel Mutnick、Wenshuo Lu、Arnab Chatterjee、Michael J. Roberts、Yun He、Donald S. Karanewsky、Donald Chow、Jianmin Lao、Andrea Gerken、Tove Tuntland、Bo Liu、Jonathan Chang、Perry Gordon、H. Martin Seidel、Shin-Shay Tian

  DOI：10.1016/j.bmcl.2008.08.068

  日期：2008.10

  A novel series of benzo[a] carbazole-based small molecule agonists of the thrombopoietin (Tpo) receptor is reported. Starting from a 3.4 mu M high throughput screen hit, members of this series have been identified which are full agonists with functional potency < 50 nM and oral bioavailability in mice. (C) 2008 Elsevier Ltd. All rights reserved.